CSL Behring News
HAEGARDA® is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies
King of Prussia, Pa. and Sioux Falls, S.D., April 8, 2020
COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology,
on-track for clinical evaluation as early as summer
Osaka, JAPAN, and King of Prussia, PA, USA
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.
HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Now approved by Health Canada: Hizentra® (Subcutaneous Immunoglobulin [Human] 20% Liquid) for the Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for maintenance therapy
Ottawa – CSL Behring has shipped more than 10 million international units (IUs) of its medicines to treat hemophilia A to the WFH Global Alliance for Progress (GAP)Program in recognition of World Hemophilia Day.